glecaprevir pibrentasvir
Selected indexed studies
- Glecaprevir/Pibrentasvir: First Global Approval. (Drugs, 2017) [PMID:28929412]
- Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. (Future Microbiol, 2019) [PMID:30499343]
- Glecaprevir/pibrentasvir for hepatitis C. (Aust Prescr, 2018) [PMID:30410216]
_Worker-drafted node — pending editorial review._
Connections
glecaprevir pibrentasvir is a side effect of
Sources
- Glecaprevir/Pibrentasvir: First Global Approval. (2017) pubmed
- Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. (2019) pubmed
- Glecaprevir/pibrentasvir for hepatitis C. (2018) pubmed
- Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. (2020) pubmed
- Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. (2018) pubmed
- Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta-Analysis. (2025) pubmed
- Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. (2019) pubmed
- Glecaprevir + pibrentasvir for treatment of hepatitis C. (2018) pubmed
- PMID:41397063 (2018) pubmed
- Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults. (2018) pubmed